Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review
August 2019
50
About the Report
About the Report
Oxford BioMedica Plc (OXB)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description-A detailed description of the company's operations and business divisions.
- Corporate strategy-Analyst's summarization of the company's business strategy.
- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history-Progression of key events associated with the company.
- Major products and services-A list of major products, services and brands of the company.
- Key competitors-A list of key competitors to the company.
- Key employees-A list of the key executives of the company.
- Executive biographies-A brief summary of the executives' employment history.
- Key operational heads-A list of personnel heading key departments/functions.
- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Oxford BioMedica plc (Oxford Biomedica) is a biopharmaceutical company involved in the development and commercialization of gene based medicines. It has LentiVector, a sector leading lentiviral vector delivery platform. Based on this platform the company has developed a portfolio of gene and cell therapy product candidates in ophthalmology, oncology and central nervous system (CNS) therapy areas. It has partnership and license agreement with other companies to develop potential gene and cell therapy products. The company has presence in different locations in Oxfordshire UK. Oxford BioMedica is headquartered in Oxford, the UK.
Oxford BioMedica Plc Key Recent Developments
Jun 28,2019: Oxford Biomedica: Repayment of debt facility
Jun 26,2019: OXB and Santen to develop gene therapy products for retinal disease
Jun 25,2019: Oxford Biomedica appoints Robert Ghenchev as Non-Executive Director
Mar 14,2019: Oxford Biomedica : preliminary results for the year ended 31 December 2018
Mar 12,2019: Microsoft unveils new platform to boost therapeutics production
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Products
Products
Oxford BioMedica Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Companies
Vernalis Plc
Transgene SA
Summit Therapeutics Plc
Proteome Sciences Plc
Phynova Group Ltd
Almac Group Ltd
Alliance Pharma Plc
Agenus Inc
Table of Contents
Table of Contents
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1-About the Company
Oxford BioMedica Plc-Key Facts
Oxford BioMedica Plc-Key Employees
Oxford BioMedica Plc-Key Employee Biographies
Oxford BioMedica Plc-Major Products and Services
Oxford BioMedica Plc-History
Oxford BioMedica Plc-Company Statement
Oxford BioMedica Plc-Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2-Company Analysis
Company Overview
Oxford BioMedica Plc-Business Description
Oxford BioMedica Plc-SWOT Analysis
SWOT Analysis-Overview
Oxford BioMedica Plc-Strengths
Oxford BioMedica Plc-Weaknesses
Oxford BioMedica Plc-Opportunities
Oxford BioMedica Plc-Threats
Oxford BioMedica Plc-Key Competitors
Section 3-Company Financial Ratios
Financial Ratios-Capital Market Ratios
Financial Ratios-Annual Ratios
Performance Chart
Financial Performance
Financial Ratios-Interim Ratios
Financial Ratios-Ratio Charts
Section 4-Company's Lifesciences Financial Deals and Alliances
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Oxford BioMedica Plc, Recent Deals Summary
Section 5-Company's Recent Developments
Jun 28, 2019: Oxford Biomedica: Repayment of debt facility
Jun 26, 2019: OXB and Santen to develop gene therapy products for retinal disease
Jun 25, 2019: Oxford Biomedica appoints Robert Ghenchev as Non-Executive Director
Mar 14, 2019: Oxford Biomedica : preliminary results for the year ended 31 December 2018
Mar 12, 2019: Microsoft unveils new platform to boost therapeutics production
Mar 12, 2019: Oxford Biomedica announces R&D collaboration with Microsoft to improve gene and cell therapy manufacturing using the intelligent cloud and machine learning
Mar 05, 2019: CGT Catapult Celebrates First Successful Months of Novel Apprenticeship Programme to Secure Future Skills for Advanced Therapies
Feb 21, 2019: International biomed specialist appoints WHP to deliver key expansion project
Nov 23, 2018: Oxford BioMedica announces new digital framework initiative to streamline the production of next-generation medicines with cash injection from Innovate UK
Nov 22, 2018: Manufacturing of life-enhancing medicines boosted by new government funding
Section 6-Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Figure
List of Figures
Oxford BioMedica Plc, Performance Chart (2014-2018)
Oxford BioMedica Plc, Ratio Charts
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
List of Table
List of Tables
Oxford BioMedica Plc, Key Facts
Oxford BioMedica Plc, Key Employees
Oxford BioMedica Plc, Key Employee Biographies
Oxford BioMedica Plc, Major Products and Services
Oxford BioMedica Plc, History
Oxford BioMedica Plc, Other Locations
Oxford BioMedica Plc, Subsidiaries
Oxford BioMedica Plc, Key Competitors
Oxford BioMedica Plc, Ratios based on current share price
Oxford BioMedica Plc, Annual Ratios
Oxford BioMedica Plc, Annual Ratios (Cont...1)
Oxford BioMedica Plc, Interim Ratios
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Oxford BioMedica Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.